Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy
An analysis of the Castor trial
Maiese, E. M., Graham, CN., Hawe, E., Le Moine, J-G., Abraham, I., & Senbetta, M. (2017). Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: An analysis of the Castor trial. Blood, 130.
Publications Info
To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.